Clinical Trials
262
Active:13
Completed:26
Trial Phases
6 Phases
Early Phase 1:9
Phase 1:48
Phase 2:108
+3 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (236 trials with phase data)• Click on a phase to view related trials
Phase 2
108 (45.8%)Not Applicable
53 (22.5%)Phase 1
48 (20.3%)Phase 4
13 (5.5%)Early Phase 1
9 (3.8%)Phase 3
5 (2.1%)ASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Primary Plasma Cell Leukemia
Not Applicable
Recruiting
- Conditions
- Multiple Myeloma, Plasma Cell Leukemia
- Interventions
- Procedure: Autologous hematopoietic stem cell transplantationDrug: GPRC5D/CD3 BiTEs
- First Posted Date
- 2025-08-06
- Last Posted Date
- 2025-08-06
- Target Recruit Count
- 20
- Registration Number
- NCT07106684
- Locations
- 🇨🇳
Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences, Tianjin, Tianjin, China
Clinical Study of the Safety and Efficacy of ASCT Combined With CD7-CART in the Treatment of CD7+ TCL
Not Applicable
Recruiting
- Conditions
- CD7 PositiveT - Cell Lymphoma
- Interventions
- Drug: ASCT+CD7-CART
- First Posted Date
- 2025-08-06
- Last Posted Date
- 2025-08-06
- Target Recruit Count
- 50
- Registration Number
- NCT07106723
- Locations
- 🇨🇳
Blood Disease Hospital, Chinese Academy of Medical Sciences, Tianjin, Tianjin, China
ASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Ultra-High-Risk Multiple Myeloma
Not Applicable
Recruiting
- Conditions
- Multiple Myeloma, Newly Diagnosed
- Interventions
- Procedure: Autologous Hematopoietic Stem Cell TransplantationDrug: GPRC5D/CD3 BiTEs
- First Posted Date
- 2025-08-06
- Last Posted Date
- 2025-08-06
- Target Recruit Count
- 30
- Registration Number
- NCT07106710
- Locations
- 🇨🇳
Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences, Tianjin, Tianjin, China
MRD-Adaptive Guided Immunotherapy With CAR-T for Transplant-Ineligible Patients With Multiple Myeloma
Not Applicable
Recruiting
- Conditions
- Multiple Myeloma, Newly Diagnosed
- Interventions
- Drug: GPRC5D/CD3 BiTEs
- First Posted Date
- 2025-08-06
- Last Posted Date
- 2025-08-06
- Target Recruit Count
- 60
- Registration Number
- NCT07106736
- Locations
- 🇨🇳
Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences, Tianjin, Tianjin, China
A Phase II Study of Siltuximab for CRS/ICANs After CAR-T in Multiple Myeloma
Not Applicable
Recruiting
- Conditions
- CRS - Cytokine Release SyndromeMyeloma
- Interventions
- First Posted Date
- 2025-08-06
- Last Posted Date
- 2025-08-06
- Target Recruit Count
- 20
- Registration Number
- NCT07106671
- Locations
- 🇨🇳
Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences, Tianjin, China
- Prev
- 1
- 2
- 3
- 4
- 5
- 53
- Next
News
No news found